The therapeutic role of naltrexone in negative symptom schizophrenia
1. 1. Naltrexone (50 mg bid, p.o.) was administered in a double-blind fashion (with placebo control) to chronic schizophrenic patients who maintained their routine neuroleptic and anxiolytic therapy. 2. 2. Both positive and negative symptom patients who received naltrexone improved with regard to sy...
Gespeichert in:
| Veröffentlicht in: | Progress in neuro-psychopharmacology & biological psychiatry 1995-12, Vol.19 (8), p.1239-1249 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1249 |
|---|---|
| container_issue | 8 |
| container_start_page | 1239 |
| container_title | Progress in neuro-psychopharmacology & biological psychiatry |
| container_volume | 19 |
| creator | Marchesi, Gian Franco Santone, Giovanni Cotani, Paolo Giordano, Antonio Chelli, Francesco |
| description | 1.
1. Naltrexone (50 mg bid, p.o.) was administered in a double-blind fashion (with placebo control) to chronic schizophrenic patients who maintained their routine neuroleptic and anxiolytic therapy.
2.
2. Both positive and negative symptom patients who received naltrexone improved with regard to symptoms involving deterioration and social withdrawal. No significant amelioration was recorded in subjects assuming placebo relative to the same psychopathological areas.
3.
3. Favourable results were obtained mainly from patients affected by negative symptom schizophrenia.
4.
4. Naltrexone may have acted by direct or indirect neurochemical mechanisms related to negative symptom schizophrenia. |
| doi_str_mv | 10.1016/0278-5846(95)00263-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77933392</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0278584695002634</els_id><sourcerecordid>77933392</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-1588275a14fa1d26603efcace7ed3ef518b53ee0baedc3f7b0c4a1423ba2abfe3</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRaq3-A4UcRPQQ3Y9kd3MRpH5CwUs9L5vNxK4k2bibFOuvN7WlRz3NMO8zw_AgdErwNcGE32AqZJzKhF9m6RXGlLM42UNjIodxQgnfR-MdcoiOQvjAGBOG2QiNpOSSYj5G9_MFRN0CvG6h76yJvKsgcmXU6Krz8OUaiGwTNfCuO7uEKKzqtnN1FMzCfrt24aGx-hgdlLoKcLKtE_T2-DCfPsez16eX6d0sNgkRXUxSKalINUlKTQrKOWZQGm1AQDF0KZF5ygBwrqEwrBQ5NskAU5ZrqvMS2ARdbO623n32EDpV22CgqnQDrg9KiIwxltF_QSIw4zTFA5hsQONdCB5K1Xpba79SBKu1ZbVWqNYKVZaqX8sqGdbOtvf7vIZit7TVOuTn21wHo6vS68bYsMNoJqRkYsBuNxgM0pYWvArGQmOgsB5Mpwpn__7jB-lMmag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17036250</pqid></control><display><type>article</type><title>The therapeutic role of naltrexone in negative symptom schizophrenia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Marchesi, Gian Franco ; Santone, Giovanni ; Cotani, Paolo ; Giordano, Antonio ; Chelli, Francesco</creator><creatorcontrib>Marchesi, Gian Franco ; Santone, Giovanni ; Cotani, Paolo ; Giordano, Antonio ; Chelli, Francesco</creatorcontrib><description>1.
1. Naltrexone (50 mg bid, p.o.) was administered in a double-blind fashion (with placebo control) to chronic schizophrenic patients who maintained their routine neuroleptic and anxiolytic therapy.
2.
2. Both positive and negative symptom patients who received naltrexone improved with regard to symptoms involving deterioration and social withdrawal. No significant amelioration was recorded in subjects assuming placebo relative to the same psychopathological areas.
3.
3. Favourable results were obtained mainly from patients affected by negative symptom schizophrenia.
4.
4. Naltrexone may have acted by direct or indirect neurochemical mechanisms related to negative symptom schizophrenia.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/0278-5846(95)00263-4</identifier><identifier>PMID: 8868206</identifier><identifier>CODEN: PNPPD7</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Adult ; Antipsychotic Agents - therapeutic use ; Biological and medical sciences ; Chronic Disease ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; naltrexone ; Naltrexone - therapeutic use ; Narcotic Antagonists - therapeutic use ; Neuropharmacology ; opioid peptides ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; schizophrenia ; Schizophrenia - drug therapy ; Schizophrenic Psychology ; Treatment Outcome</subject><ispartof>Progress in neuro-psychopharmacology & biological psychiatry, 1995-12, Vol.19 (8), p.1239-1249</ispartof><rights>1995</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-1588275a14fa1d26603efcace7ed3ef518b53ee0baedc3f7b0c4a1423ba2abfe3</citedby><cites>FETCH-LOGICAL-c417t-1588275a14fa1d26603efcace7ed3ef518b53ee0baedc3f7b0c4a1423ba2abfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0278584695002634$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2978837$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8868206$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marchesi, Gian Franco</creatorcontrib><creatorcontrib>Santone, Giovanni</creatorcontrib><creatorcontrib>Cotani, Paolo</creatorcontrib><creatorcontrib>Giordano, Antonio</creatorcontrib><creatorcontrib>Chelli, Francesco</creatorcontrib><title>The therapeutic role of naltrexone in negative symptom schizophrenia</title><title>Progress in neuro-psychopharmacology & biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>1.
1. Naltrexone (50 mg bid, p.o.) was administered in a double-blind fashion (with placebo control) to chronic schizophrenic patients who maintained their routine neuroleptic and anxiolytic therapy.
2.
2. Both positive and negative symptom patients who received naltrexone improved with regard to symptoms involving deterioration and social withdrawal. No significant amelioration was recorded in subjects assuming placebo relative to the same psychopathological areas.
3.
3. Favourable results were obtained mainly from patients affected by negative symptom schizophrenia.
4.
4. Naltrexone may have acted by direct or indirect neurochemical mechanisms related to negative symptom schizophrenia.</description><subject>Adult</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>naltrexone</subject><subject>Naltrexone - therapeutic use</subject><subject>Narcotic Antagonists - therapeutic use</subject><subject>Neuropharmacology</subject><subject>opioid peptides</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><subject>Treatment Outcome</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1Lw0AQhhdRaq3-A4UcRPQQ3Y9kd3MRpH5CwUs9L5vNxK4k2bibFOuvN7WlRz3NMO8zw_AgdErwNcGE32AqZJzKhF9m6RXGlLM42UNjIodxQgnfR-MdcoiOQvjAGBOG2QiNpOSSYj5G9_MFRN0CvG6h76yJvKsgcmXU6Krz8OUaiGwTNfCuO7uEKKzqtnN1FMzCfrt24aGx-hgdlLoKcLKtE_T2-DCfPsez16eX6d0sNgkRXUxSKalINUlKTQrKOWZQGm1AQDF0KZF5ygBwrqEwrBQ5NskAU5ZrqvMS2ARdbO623n32EDpV22CgqnQDrg9KiIwxltF_QSIw4zTFA5hsQONdCB5K1Xpba79SBKu1ZbVWqNYKVZaqX8sqGdbOtvf7vIZit7TVOuTn21wHo6vS68bYsMNoJqRkYsBuNxgM0pYWvArGQmOgsB5Mpwpn__7jB-lMmag</recordid><startdate>19951201</startdate><enddate>19951201</enddate><creator>Marchesi, Gian Franco</creator><creator>Santone, Giovanni</creator><creator>Cotani, Paolo</creator><creator>Giordano, Antonio</creator><creator>Chelli, Francesco</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>19951201</creationdate><title>The therapeutic role of naltrexone in negative symptom schizophrenia</title><author>Marchesi, Gian Franco ; Santone, Giovanni ; Cotani, Paolo ; Giordano, Antonio ; Chelli, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-1588275a14fa1d26603efcace7ed3ef518b53ee0baedc3f7b0c4a1423ba2abfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>naltrexone</topic><topic>Naltrexone - therapeutic use</topic><topic>Narcotic Antagonists - therapeutic use</topic><topic>Neuropharmacology</topic><topic>opioid peptides</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marchesi, Gian Franco</creatorcontrib><creatorcontrib>Santone, Giovanni</creatorcontrib><creatorcontrib>Cotani, Paolo</creatorcontrib><creatorcontrib>Giordano, Antonio</creatorcontrib><creatorcontrib>Chelli, Francesco</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marchesi, Gian Franco</au><au>Santone, Giovanni</au><au>Cotani, Paolo</au><au>Giordano, Antonio</au><au>Chelli, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The therapeutic role of naltrexone in negative symptom schizophrenia</atitle><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>1995-12-01</date><risdate>1995</risdate><volume>19</volume><issue>8</issue><spage>1239</spage><epage>1249</epage><pages>1239-1249</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><coden>PNPPD7</coden><abstract>1.
1. Naltrexone (50 mg bid, p.o.) was administered in a double-blind fashion (with placebo control) to chronic schizophrenic patients who maintained their routine neuroleptic and anxiolytic therapy.
2.
2. Both positive and negative symptom patients who received naltrexone improved with regard to symptoms involving deterioration and social withdrawal. No significant amelioration was recorded in subjects assuming placebo relative to the same psychopathological areas.
3.
3. Favourable results were obtained mainly from patients affected by negative symptom schizophrenia.
4.
4. Naltrexone may have acted by direct or indirect neurochemical mechanisms related to negative symptom schizophrenia.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>8868206</pmid><doi>10.1016/0278-5846(95)00263-4</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-5846 |
| ispartof | Progress in neuro-psychopharmacology & biological psychiatry, 1995-12, Vol.19 (8), p.1239-1249 |
| issn | 0278-5846 1878-4216 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77933392 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Antipsychotic Agents - therapeutic use Biological and medical sciences Chronic Disease Double-Blind Method Drug Therapy, Combination Female Humans Male Medical sciences Middle Aged naltrexone Naltrexone - therapeutic use Narcotic Antagonists - therapeutic use Neuropharmacology opioid peptides Pharmacology. Drug treatments Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology schizophrenia Schizophrenia - drug therapy Schizophrenic Psychology Treatment Outcome |
| title | The therapeutic role of naltrexone in negative symptom schizophrenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T15%3A54%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20therapeutic%20role%20of%20naltrexone%20in%20negative%20symptom%20schizophrenia&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Marchesi,%20Gian%20Franco&rft.date=1995-12-01&rft.volume=19&rft.issue=8&rft.spage=1239&rft.epage=1249&rft.pages=1239-1249&rft.issn=0278-5846&rft.eissn=1878-4216&rft.coden=PNPPD7&rft_id=info:doi/10.1016/0278-5846(95)00263-4&rft_dat=%3Cproquest_cross%3E77933392%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17036250&rft_id=info:pmid/8868206&rft_els_id=0278584695002634&rfr_iscdi=true |